To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

Inclusion Criteria

• •1. Understand the purpose and risks of the study and provide informed consent in accordance with national and local privacy laws:
• •2. Subject must be male, aged ≥18 years old at the time of signing informed consent:
• •3. Participants with confirmed severe hemophilia A in their pre-admission history and based on clinical laboratory examination;
• •4. Subjects had used FVIII products for at least 150 exposure days (ED) before enrollment;
• •5. Subject has received continuous prophylactic treatment with exogenous FVIII for one year prior to enrollment or has been treated with exogenous FVIII on demand;
• •6. Subject has no history of hypersensitivity or allergic reactions related to the administration of FVIII agents;
• •7. Subject has no history of FVIII inhibitors.
• •8. Subjects agree to use a reliable barrier contraceptive method from the date of signing the informed consent
• •9. Subject is willing and able to follow planned visits, treatment plans, and other study procedures.